|
1 Introduction to the Clinical Immunology laboratory |
|
|
1 | (5) |
|
|
|
|
1 | (1) |
|
|
2 | (1) |
|
1.2 Immunology in biomedical science |
|
|
3 | (3) |
|
|
5 | (1) |
|
|
5 | (1) |
|
|
6 | (37) |
|
|
|
|
6 | (1) |
|
|
6 | (6) |
|
2.2 The monoclonal gammopathies |
|
|
12 | (2) |
|
2.3 Quantification of immunoglobulins |
|
|
14 | (19) |
|
2.4 Cerebrospinal fluid and isoelectric focusing |
|
|
33 | (4) |
|
|
37 | (6) |
|
|
40 | (1) |
|
|
41 | (1) |
|
|
42 | (1) |
|
|
43 | (32) |
|
|
|
43 | (1) |
|
|
43 | (1) |
|
|
44 | (1) |
|
|
45 | (1) |
|
3.4 Clinical features of allergic diseases |
|
|
46 | (3) |
|
|
49 | (4) |
|
3.6 Allergen-specific IgE tests |
|
|
53 | (1) |
|
3.7 Allergen standardization |
|
|
54 | (1) |
|
|
55 | (2) |
|
3.9 Component resolved diagnostics |
|
|
57 | (2) |
|
3.10 Microarray-based allergy testing |
|
|
59 | (2) |
|
3.11 Total IgE measurements |
|
|
61 | (1) |
|
3.12 Quality assurance of laboratory allergy tests |
|
|
62 | (1) |
|
3.13 Flow cytometric basophil activation test |
|
|
63 | (5) |
|
3.14 Measurement of mediators released during allergic reactions |
|
|
68 | (3) |
|
3.15 IgG antibodies in hypersensitivity |
|
|
71 | (4) |
|
|
73 | (1) |
|
|
73 | (1) |
|
|
74 | (1) |
|
|
75 | (24) |
|
|
|
|
|
|
|
75 | (1) |
|
4.1 Actions of complement |
|
|
76 | (3) |
|
4.2 Regulation of complement |
|
|
79 | (1) |
|
4.3 Complement deficiencies |
|
|
80 | (4) |
|
4.4 Measurement of complement activity |
|
|
84 | (7) |
|
4.5 C1 inhibitor deficiency |
|
|
91 | (4) |
|
4.6 Auto-antibodies against complement components and complexes |
|
|
95 | (1) |
|
4.7 Complement allotyping |
|
|
96 | (1) |
|
4.8 Molecular testing for complement deficiencies |
|
|
96 | (3) |
|
|
97 | (1) |
|
|
97 | (1) |
|
|
98 | (1) |
|
5 Autoimmune rheumatological disease |
|
|
99 | (21) |
|
|
|
99 | (1) |
|
5.1 Systemic lupus erythematosus (SLE) |
|
|
100 | (2) |
|
5.2 Rheumatoid arthritis (RA) |
|
|
102 | (3) |
|
|
105 | (2) |
|
|
107 | (1) |
|
5.5 Polymyositis and dermatomyositis |
|
|
107 | (1) |
|
5.6 Antiphospholipid syndrome (APS) |
|
|
107 | (2) |
|
5.7 Overlapping connective tissue diseases |
|
|
109 | (1) |
|
|
110 | (10) |
|
|
118 | (1) |
|
|
118 | (1) |
|
|
119 | (1) |
|
6 Autoimmune kidney disease |
|
|
120 | (19) |
|
|
|
120 | (1) |
|
6.1 Vasculitis and classification |
|
|
121 | (2) |
|
6.2 Microscopic polyangiitis (MPA) |
|
|
123 | (1) |
|
6.3 Granulomatosis with polyangiitis (Wegener's) (GPA) |
|
|
124 | (1) |
|
6.4 Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) |
|
|
124 | (1) |
|
6.5 Anti-GBM disease (Goodpasture's syndrome) |
|
|
125 | (1) |
|
6.6 Membranous nephropathy (MN) |
|
|
125 | (1) |
|
6.7 Pathogenesis of renal related auto-antibodies |
|
|
126 | (1) |
|
6.8 Treatment and prognosis of autoimmune renal disease |
|
|
127 | (1) |
|
6.9 Auto-antibodies in autoimmune kidney diseases |
|
|
128 | (11) |
|
|
137 | (1) |
|
|
138 | (1) |
|
|
138 | (1) |
|
7 Organ-specific autoimmunity |
|
|
139 | (31) |
|
|
|
139 | (2) |
|
7.1 Autoimmune thyroid disease |
|
|
141 | (7) |
|
|
148 | (8) |
|
|
156 | (3) |
|
7.4 Autoimmune endocrinopathies |
|
|
159 | (11) |
|
|
168 | (1) |
|
|
168 | (1) |
|
|
169 | (1) |
|
8 Autoimmune skin disease |
|
|
170 | (18) |
|
|
|
|
|
170 | (1) |
|
|
171 | (1) |
|
|
172 | (5) |
|
|
177 | (6) |
|
8.4 Other autoimmune blistering skin disorders |
|
|
183 | (5) |
|
|
186 | (1) |
|
|
187 | (1) |
|
|
187 | (1) |
|
|
187 | (1) |
|
9 Autoimmune liver diseases |
|
|
188 | (22) |
|
|
|
188 | (1) |
|
9.1 Autoimmune hepatitis (AIH) |
|
|
189 | (8) |
|
9.2 Autoimmune sclerosing cholangitis (ASC) |
|
|
197 | (2) |
|
9.3 Primary biliary cirrhosis (PBC) |
|
|
199 | (5) |
|
|
204 | (2) |
|
|
206 | (4) |
|
|
208 | (1) |
|
|
209 | (1) |
|
|
209 | (1) |
|
|
210 | (42) |
|
|
|
|
210 | (3) |
|
|
213 | (1) |
|
|
213 | (1) |
|
10.3 Clinical features of paraneoplastic syndromes |
|
|
214 | (7) |
|
10.4 Malignancies commonly associated with PNS |
|
|
221 | (1) |
|
10.5 Paraneoplastic neurological antibodies (PNA) |
|
|
221 | (5) |
|
10.6 Well-characterized paraneoplastic antibodies |
|
|
226 | (8) |
|
10.7 Partially characterized paraneoplastic antibodies |
|
|
234 | (4) |
|
10.8 Pathogenic antibodies with or without cancer |
|
|
238 | (7) |
|
10.9 Miscellaneous antibodies |
|
|
245 | (7) |
|
|
250 | (1) |
|
|
250 | (1) |
|
|
251 | (1) |
|
11 Flow cytometry and primary immunodeficiency |
|
|
252 | (30) |
|
|
|
252 | (1) |
|
|
253 | (5) |
|
|
258 | (6) |
|
|
264 | (2) |
|
11.4 Natural killer (NK) cells |
|
|
266 | (1) |
|
11.5 Additional antibodies |
|
|
267 | (3) |
|
|
270 | (3) |
|
11.7 Intracellular staining |
|
|
273 | (1) |
|
|
273 | (2) |
|
|
275 | (7) |
|
|
280 | (1) |
|
|
281 | (1) |
|
|
281 | (1) |
|
12 Human immunodeficiency virus (HIV) |
|
|
282 | (17) |
|
|
|
282 | (1) |
|
12.1 The human immunodeficiency virus |
|
|
283 | (1) |
|
12.2 The life cycle of HIV |
|
|
283 | (2) |
|
|
285 | (1) |
|
12.4 Effects of HIV on the immune system |
|
|
285 | (1) |
|
12.5 Clinical features of HIV infection |
|
|
286 | (1) |
|
|
287 | (1) |
|
12.7 Laboratory diagnosis of HIV infection |
|
|
288 | (4) |
|
12.8 Treatment regimens for HIV-1 infections |
|
|
292 | (3) |
|
12.9 Prevention of HIV transmission and infection |
|
|
295 | (4) |
|
|
298 | (1) |
|
|
298 | (1) |
|
13 Histocompatibility and immunogenetics |
|
|
299 | (22) |
|
|
|
|
299 | (1) |
|
13.1 The major histocompatibility complex (MHC) |
|
|
300 | (1) |
|
|
301 | (2) |
|
|
303 | (2) |
|
13.4 HLA antibody testing |
|
|
305 | (1) |
|
13.5 Solid organ transplantation |
|
|
306 | (7) |
|
13.6 Post-transplant monitoring |
|
|
313 | (1) |
|
13.7 Haematopoietic progenitor cell transplantation |
|
|
314 | (1) |
|
|
314 | (7) |
|
|
318 | (1) |
|
|
319 | (1) |
|
|
319 | (2) |
References |
|
321 | (6) |
Glossary |
|
327 | (4) |
Abbreviations |
|
331 | (2) |
Hints and tips for discussion questions |
|
333 | (6) |
Index |
|
339 | |